Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
出版年份 2016 全文链接
标题
Prognostic and predictive impacts of tumor-infiltrating lymphocytes differ between Triple-negative and HER2-positive breast cancers treated with standard systemic therapies
作者
关键词
Tumor-infiltrating lymphocyte, Triple-negative, HER2-positive, Breast cancer
出版物
BREAST CANCER RESEARCH AND TREATMENT
Volume 158, Issue 1, Pages 1-9
出版商
Springer Nature
发表日期
2016-06-03
DOI
10.1007/s10549-016-3848-2
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Association of Stromal Tumor-Infiltrating Lymphocytes With Recurrence-Free Survival in the N9831 Adjuvant Trial in Patients With Early-Stage HER2-Positive Breast Cancer
- (2016) Edith A. Perez et al. JAMA Oncology
- Evaluation of tumor-infiltrating lymphocytes in breast cancer; proposal of a simpler method
- (2015) A. I. Hida et al. ANNALS OF ONCOLOGY
- Prognostic and predictive value of tumor-infiltrating lymphocytes in two phase III randomized adjuvant breast cancer trials
- (2015) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Tailoring therapies—improving the management of early breast cancer: St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2015
- (2015) A. S. Coates et al. ANNALS OF ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Response to Neoadjuvant Chemotherapy With or Without Carboplatin in Human Epidermal Growth Factor Receptor 2–Positive and Triple-Negative Primary Breast Cancers
- (2015) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune Checkpoint Blockade in Cancer Therapy
- (2015) Michael A. Postow et al. JOURNAL OF CLINICAL ONCOLOGY
- Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab
- (2015) Roberto Salgado et al. JAMA Oncology
- Prognostic value of tumor-infiltrating lymphocytes on residual disease after primary chemotherapy for triple-negative breast cancer: a retrospective multicenter study
- (2014) M. V. Dieci et al. ANNALS OF ONCOLOGY
- Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial
- (2014) S. Loi et al. ANNALS OF ONCOLOGY
- The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014
- (2014) R. Salgado et al. ANNALS OF ONCOLOGY
- Prognostic Value of Tumor-Infiltrating Lymphocytes in Triple-Negative Breast Cancers From Two Phase III Randomized Adjuvant Breast Cancer Trials: ECOG 2197 and ECOG 1199
- (2014) Sylvia Adams et al. JOURNAL OF CLINICAL ONCOLOGY
- The immune system and response to HER2-targeted treatment in breast cancer
- (2014) Giampaolo Bianchini et al. LANCET ONCOLOGY
- Prognostic and Predictive Value of Tumor-Infiltrating Lymphocytes in a Phase III Randomized Adjuvant Breast Cancer Trial in Node-Positive Breast Cancer Comparing the Addition of Docetaxel to Doxorubicin With Doxorubicin-Based Chemotherapy: BIG 02-98
- (2013) Sherene Loi et al. JOURNAL OF CLINICAL ONCOLOGY
- A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application
- (2013) Taku Okazaki et al. NATURE IMMUNOLOGY
- The prognostic influence of tumour-infiltrating lymphocytes in cancer: a systematic review with meta-analysis
- (2011) M J M Gooden et al. BRITISH JOURNAL OF CANCER
- The Therapeutic Effect of Anti-HER2/neu Antibody Depends on Both Innate and Adaptive Immunity
- (2010) SaeGwang Park et al. CANCER CELL
- Tumor-Associated Lymphocytes As an Independent Predictor of Response to Neoadjuvant Chemotherapy in Breast Cancer
- (2009) Carsten Denkert et al. JOURNAL OF CLINICAL ONCOLOGY
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started